Table of Content

1 Report Overview
1.1 Influenza Medication Definition
1.2 Market by Type
1.2.1 Global Influenza Medication Market Size Growth Rate by Type, 2018 VS 2022 VS 2034
1.2.2 Zanamivir
1.2.3 Oseltamivir
1.2.4 Peramivir
1.2.5 Amantadine
1.2.6 Rimantadine
1.2.7 Inosine
1.2.8 Others
1.3 Market Segment by Application
1.3.1 Global Influenza Medication Market Size Growth Rate by Application, 2018 VS 2022 VS 2034
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Pharmacies
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Influenza Medication Sales
2.1 Global Influenza Medication Revenue Estimates and Forecasts 2018-2034
2.2 Global Influenza Medication Revenue by Region: 2018 VS 2022 VS 2034
2.3 Global Influenza Medication Revenue by Region
2.3.1 Global Influenza Medication Revenue by Region (2018-2024)
2.3.2 Global Influenza Medication Revenue by Region (2024-2034)
2.4 Global Influenza Medication Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Influenza Medication Sales Quantity by Region: 2018 VS 2022 VS 2034
2.6 Global Influenza Medication Sales Quantity by Region
2.6.1 Global Influenza Medication Sales Quantity by Region (2018-2024)
2.6.2 Global Influenza Medication Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Influenza Medication Sales Quantity by Manufacturers
3.1.1 Global Influenza Medication Sales Quantity by Manufacturers (2018-2024)
3.1.2 Global Influenza Medication Sales Quantity Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Companies by Influenza Medication Sales in 2022
3.2 Global Influenza Medication Revenue by Manufacturers
3.2.1 Global Influenza Medication Revenue by Manufacturers (2018-2024)
3.2.2 Global Influenza Medication Revenue Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Influenza Medication Revenue in 2022
3.3 Global Influenza Medication Sales Price by Manufacturers
3.4 Global Key Players of Influenza Medication, Industry Ranking, 2021 VS 2022
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Influenza Medication Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Influenza Medication, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Influenza Medication, Product Offered and Application
3.8 Global Key Manufacturers of Influenza Medication, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Influenza Medication Sales Quantity by Type
4.1.1 Global Influenza Medication Historical Sales Quantity by Type (2018-2024)
4.1.2 Global Influenza Medication Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Influenza Medication Sales Quantity Market Share by Type (2018-2034)
4.2 Global Influenza Medication Revenue by Type
4.2.1 Global Influenza Medication Historical Revenue by Type (2018-2024)
4.2.2 Global Influenza Medication Forecasted Revenue by Type (2024-2034)
4.2.3 Global Influenza Medication Revenue Market Share by Type (2018-2034)
4.3 Global Influenza Medication Price by Type
4.3.1 Global Influenza Medication Price by Type (2018-2024)
4.3.2 Global Influenza Medication Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Influenza Medication Sales Quantity by Application
5.1.1 Global Influenza Medication Historical Sales Quantity by Application (2018-2024)
5.1.2 Global Influenza Medication Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Influenza Medication Sales Quantity Market Share by Application (2018-2034)
5.2 Global Influenza Medication Revenue by Application
5.2.1 Global Influenza Medication Historical Revenue by Application (2018-2024)
5.2.2 Global Influenza Medication Forecasted Revenue by Application (2024-2034)
5.2.3 Global Influenza Medication Revenue Market Share by Application (2018-2034)
5.3 Global Influenza Medication Price by Application
5.3.1 Global Influenza Medication Price by Application (2018-2024)
5.3.2 Global Influenza Medication Price Forecast by Application (2024-2034)
6 North America
6.1 North America Influenza Medication Sales by Company
6.1.1 North America Influenza Medication Revenue by Company (2018-2024)
6.1.2 North America Influenza Medication Sales Quantity by Company (2018-2024)
6.2 North America Influenza Medication Market Size by Type
6.2.1 North America Influenza Medication Sales Quantity by Type (2018-2034)
6.2.2 North America Influenza Medication Revenue by Type (2018-2034)
6.3 North America Influenza Medication Market Size by Application
6.3.1 North America Influenza Medication Sales Quantity by Application (2018-2034)
6.3.2 North America Influenza Medication Revenue by Application (2018-2034)
6.4 North America Influenza Medication Market Size by Country
6.4.1 North America Influenza Medication Revenue by Country: 2018 VS 2022 VS 2034
6.4.2 North America Influenza Medication Revenue by Country (2018-2034)
6.4.3 North America Influenza Medication Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Influenza Medication Sales by Company
7.1.1 Europe Influenza Medication Sales Quantity by Company (2018-2024)
7.1.2 Europe Influenza Medication Revenue by Company (2018-2024)
7.2 Europe Influenza Medication Market Size by Type
7.2.1 Europe Influenza Medication Sales Quantity by Type (2018-2034)
7.2.2 Europe Influenza Medication Revenue by Type (2018-2034)
7.3 Europe Influenza Medication Market Size by Application
7.3.1 Europe Influenza Medication Sales Quantity by Application (2018-2034)
7.3.2 Europe Influenza Medication Revenue by Application (2018-2034)
7.4 Europe Influenza Medication Market Size by Country
7.4.1 Europe Influenza Medication Revenue by Country: 2018 VS 2022 VS 2034
7.4.2 Europe Influenza Medication Revenue by Country (2018-2034)
7.4.3 Europe Influenza Medication Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Influenza Medication Sales by Company
8.1.1 China Influenza Medication Sales Quantity by Company (2018-2024)
8.1.2 China Influenza Medication Revenue by Company (2018-2024)
8.2 China Influenza Medication Market Size by Type
8.2.1 China Influenza Medication Sales Quantity by Type (2018-2034)
8.2.2 China Influenza Medication Revenue by Type (2018-2034)
8.3 China Influenza Medication Market Size by Application
8.3.1 China Influenza Medication Sales Quantity by Application (2018-2034)
8.3.2 China Influenza Medication Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Influenza Medication Sales by Company
9.1.1 APAC Influenza Medication Sales Quantity by Company (2018-2024)
9.1.2 APAC Influenza Medication Revenue by Company (2018-2024)
9.2 APAC Influenza Medication Market Size by Type
9.2.1 APAC Influenza Medication Sales Quantity by Type (2018-2034)
9.2.2 APAC Influenza Medication Revenue by Type (2018-2034)
9.3 APAC Influenza Medication Market Size by Application
9.3.1 APAC Influenza Medication Sales Quantity by Application (2018-2034)
9.3.2 APAC Influenza Medication Revenue by Application (2018-2034)
9.4 APAC Influenza Medication Market Size by Region
9.4.1 APAC Influenza Medication Revenue by Region: 2018 VS 2022 VS 2034
9.4.2 APAC Influenza Medication Revenue by Region (2018-2034)
9.4.3 APAC Influenza Medication Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Influenza Medication Sales by Company
10.1.1 Middle East, Africa and Latin America Influenza Medication Sales Quantity by Company (2018-2024)
10.1.2 Middle East, Africa and Latin America Influenza Medication Revenue by Company (2018-2024)
10.2 Middle East, Africa and Latin America Influenza Medication Market Size by Type
10.2.1 Middle East, Africa and Latin America Influenza Medication Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Influenza Medication Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Influenza Medication Market Size by Application
10.3.1 Middle East, Africa and Latin America Influenza Medication Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Influenza Medication Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Influenza Medication Market Size by Country
10.4.1 Middle East, Africa and Latin America Influenza Medication Revenue by Country: 2018 VS 2022 VS 2034
10.4.2 Middle East, Africa and Latin America Influenza Medication Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Influenza Medication Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 Daiichi Sankyo Company
11.1.1 Daiichi Sankyo Company Company Information
11.1.2 Daiichi Sankyo Company Overview
11.1.3 Daiichi Sankyo Company Influenza Medication Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.1.4 Daiichi Sankyo Company Influenza Medication Products and Services
11.1.5 Daiichi Sankyo Company Influenza Medication SWOT Analysis
11.1.6 Daiichi Sankyo Company Recent Developments
11.2 GlaxoSmithKline
11.2.1 GlaxoSmithKline Company Information
11.2.2 GlaxoSmithKline Overview
11.2.3 GlaxoSmithKline Influenza Medication Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.2.4 GlaxoSmithKline Influenza Medication Products and Services
11.2.5 GlaxoSmithKline Influenza Medication SWOT Analysis
11.2.6 GlaxoSmithKline Recent Developments
11.3 Natco Pharma
11.3.1 Natco Pharma Company Information
11.3.2 Natco Pharma Overview
11.3.3 Natco Pharma Influenza Medication Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.3.4 Natco Pharma Influenza Medication Products and Services
11.3.5 Natco Pharma Influenza Medication SWOT Analysis
11.3.6 Natco Pharma Recent Developments
11.4 F. Hoffmann-La Roche
11.4.1 F. Hoffmann-La Roche Company Information
11.4.2 F. Hoffmann-La Roche Overview
11.4.3 F. Hoffmann-La Roche Influenza Medication Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.4.4 F. Hoffmann-La Roche Influenza Medication Products and Services
11.4.5 F. Hoffmann-La Roche Influenza Medication SWOT Analysis
11.4.6 F. Hoffmann-La Roche Recent Developments
11.5 Teva Pharmaceutical
11.5.1 Teva Pharmaceutical Company Information
11.5.2 Teva Pharmaceutical Overview
11.5.3 Teva Pharmaceutical Influenza Medication Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.5.4 Teva Pharmaceutical Influenza Medication Products and Services
11.5.5 Teva Pharmaceutical Influenza Medication SWOT Analysis
11.5.6 Teva Pharmaceutical Recent Developments
11.6 Sandoz International
11.6.1 Sandoz International Company Information
11.6.2 Sandoz International Overview
11.6.3 Sandoz International Influenza Medication Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.6.4 Sandoz International Influenza Medication Products and Services
11.6.5 Sandoz International Influenza Medication SWOT Analysis
11.6.6 Sandoz International Recent Developments
11.7 Sun Pharmaceutical Industries
11.7.1 Sun Pharmaceutical Industries Company Information
11.7.2 Sun Pharmaceutical Industries Overview
11.7.3 Sun Pharmaceutical Industries Influenza Medication Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.7.4 Sun Pharmaceutical Industries Influenza Medication Products and Services
11.7.5 Sun Pharmaceutical Industries Influenza Medication SWOT Analysis
11.7.6 Sun Pharmaceutical Industries Recent Developments
11.8 Mylan
11.8.1 Mylan Company Information
11.8.2 Mylan Overview
11.8.3 Mylan Influenza Medication Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.8.4 Mylan Influenza Medication Products and Services
11.8.5 Mylan Influenza Medication SWOT Analysis
11.8.6 Mylan Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Influenza Medication Value Chain Analysis
12.2 Influenza Medication Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Influenza Medication Production Mode & Process
12.4 Influenza Medication Sales and Marketing
12.4.1 Influenza Medication Sales Channels
12.4.2 Influenza Medication Distributors
12.5 Influenza Medication Customers
13 Market Dynamics
13.1 Influenza Medication Industry Trends
13.2 Influenza Medication Market Drivers
13.3 Influenza Medication Market Challenges
13.4 Influenza Medication Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Influenza Medication Market Size Growth Rate (CAGR) by Type, 2018 VS 2022 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Zanamivir
Table 3. Major Manufacturers of Oseltamivir
Table 4. Major Manufacturers of Peramivir
Table 5. Major Manufacturers of Amantadine
Table 6. Major Manufacturers of Rimantadine
Table 7. Major Manufacturers of Inosine
Table 8. Major Manufacturers of Others
Table 9. Global Influenza Medication Market Size Growth Rate (CAGR) by Application, 2018 VS 2022 VS 2034 (US$ Million)
Table 10. Global Influenza Medication Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 11. Global Influenza Medication Revenue by Region (2018-2024) & (US$ Million)
Table 12. Global Influenza Medication Revenue Market Share by Region (2018-2024)
Table 13. Global Influenza Medication Revenue by Region (2024-2034) & (US$ Million)
Table 14. Global Influenza Medication Revenue Market Share by Region (2024-2034)
Table 15. Global Influenza Medication Sales Quantity by Region: 2018 VS 2022 VS 2034 (K Units)
Table 16. Global Influenza Medication Sales by Region (2018-2024) & (K Units)
Table 17. Global Influenza Medication Sales Market Share by Region (2018-2024)
Table 18. Global Influenza Medication Sales by Region (2024-2034) & (K Units)
Table 19. Global Influenza Medication Sales Market Share by Region (2024-2034)
Table 20. Global Influenza Medication Sales Quantity by Manufacturers (2018-2024) & (K Units)
Table 21. Global Influenza Medication Sales Quantity Share by Manufacturers (2018-2024)
Table 22. Global Influenza Medication Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 23. Global Influenza Medication Revenue Share by Manufacturers (2018-2024)
Table 24. Global Influenza Medication Price by Manufacturers 2018-2024 (USD/Unit)
Table 25. Global Key Players of Influenza Medication, Industry Ranking, 2021 VS 2022
Table 26. Global Influenza Medication Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 27. Global Influenza Medication by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Influenza Medication as of 2022)
Table 28. Global Key Manufacturers of Influenza Medication, Manufacturing Base Distribution and Headquarters
Table 29. Global Key Manufacturers of Influenza Medication, Product Offered and Application
Table 30. Global Key Manufacturers of Influenza Medication, Date of Enter into This Industry
Table 31. Mergers & Acquisitions, Expansion Plans
Table 32. Global Influenza Medication Sales Quantity by Type (2018-2024) & (K Units)
Table 33. Global Influenza Medication Sales Quantity by Type (2024-2034) & (K Units)
Table 34. Global Influenza Medication Sales Quantity Share by Type (2018-2024)
Table 35. Global Influenza Medication Sales Quantity Share by Type (2024-2034)
Table 36. Global Influenza Medication Revenue by Type (2018-2024) & (US$ Million)
Table 37. Global Influenza Medication Revenue by Type (2024-2034) & (US$ Million)
Table 38. Global Influenza Medication Revenue Share by Type (2018-2024)
Table 39. Global Influenza Medication Revenue Share by Type (2024-2034)
Table 40. Influenza Medication Price by Type (2018-2024) & (USD/Unit)
Table 41. Global Influenza Medication Price Forecast by Type (2024-2034) & (USD/Unit)
Table 42. Global Influenza Medication Sales Quantity by Application (2018-2024) & (K Units)
Table 43. Global Influenza Medication Sales Quantity by Application (2024-2034) & (K Units)
Table 44. Global Influenza Medication Sales Quantity Share by Application (2018-2024)
Table 45. Global Influenza Medication Sales Quantity Share by Application (2024-2034)
Table 46. Global Influenza Medication Revenue by Application (2018-2024) & (US$ Million)
Table 47. Global Influenza Medication Revenue by Application (2024-2034) & (US$ Million)
Table 48. Global Influenza Medication Revenue Share by Application (2018-2024)
Table 49. Global Influenza Medication Revenue Share by Application (2024-2034)
Table 50. Influenza Medication Price by Application (2018-2024) & (USD/Unit)
Table 51. Global Influenza Medication Price Forecast by Application (2024-2034) & (USD/Unit)
Table 52. North America Influenza Medication Revenue by Company (2018-2024) & (US$ Million)
Table 53. North America Influenza Medication Sales Quantity by Company (2018-2024) & (K Units)
Table 54. North America Influenza Medication Sales Quantity by Type (2018-2024) & (K Units)
Table 55. North America Influenza Medication Sales Quantity by Type (2024-2034) & (K Units)
Table 56. North America Influenza Medication Revenue by Type (2018-2024) & (US$ Million)
Table 57. North America Influenza Medication Revenue by Type (2024-2034) & (US$ Million)
Table 58. North America Influenza Medication Sales Quantity by Application (2018-2024) & (K Units)
Table 59. North America Influenza Medication Sales Quantity by Application (2024-2034) & (K Units)
Table 60. North America Influenza Medication Revenue by Application (2018-2024) & (US$ Million)
Table 61. North America Influenza Medication Revenue by Application (2024-2034) & (US$ Million)
Table 62. North America Influenza Medication Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 63. North America Influenza Medication Revenue by Country (2018-2024) & (US$ Million)
Table 64. North America Influenza Medication Revenue by Country (2024-2034) & (US$ Million)
Table 65. North America Influenza Medication Sales Quantity by Country (2018-2024) & (K Units)
Table 66. North America Influenza Medication Sales Quantity by Country (2024-2034) & (K Units)
Table 67. Europe Influenza Medication Sales Quantity by Company (2018-2024) & (K Units)
Table 68. Europe Influenza Medication Revenue by Company (2018-2024) & (US$ Million)
Table 69. Europe Influenza Medication Sales Quantity by Type (2018-2024) & (K Units)
Table 70. Europe Influenza Medication Sales Quantity by Type (2024-2034) & (K Units)
Table 71. Europe Influenza Medication Revenue by Type (2018-2024) & (US$ Million)
Table 72. Europe Influenza Medication Revenue by Type (2024-2034) & (US$ Million)
Table 73. Europe Influenza Medication Sales Quantity by Application (2018-2024) & (K Units)
Table 74. Europe Influenza Medication Sales Quantity by Application (2024-2034) & (K Units)
Table 75. Europe Influenza Medication Revenue by Application (2018-2024) & (US$ Million)
Table 76. Europe Influenza Medication Revenue by Application (2024-2034) & (US$ Million)
Table 77. Europe Influenza Medication Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 78. Europe Influenza Medication Revenue by Country (2018-2024) & (US$ Million)
Table 79. Europe Influenza Medication Revenue by Country (2024-2034) & (US$ Million)
Table 80. Europe Influenza Medication Sales Quantity by Country (2018-2024) & (K Units)
Table 81. Europe Influenza Medication Sales Quantity by Country (2024-2034) & (K Units)
Table 82. China Influenza Medication Sales Quantity by Company (2018-2024) & (K Units)
Table 83. China Influenza Medication Revenue by Company (2018-2024) & (US$ Million)
Table 84. China Influenza Medication Sales Quantity by Type (2018-2024) & (K Units)
Table 85. China Influenza Medication Sales Quantity by Type (2024-2034) & (K Units)
Table 86. China Influenza Medication Revenue by Type (2018-2024) & (US$ Million)
Table 87. China Influenza Medication Revenue by Type (2024-2034) & (US$ Million)
Table 88. China Influenza Medication Sales Quantity by Application (2018-2024) & (K Units)
Table 89. China Influenza Medication Sales Quantity by Application (2024-2034) & (K Units)
Table 90. China Influenza Medication Revenue by Application (2018-2024) & (US$ Million)
Table 91. China Influenza Medication Revenue by Application (2024-2034) & (US$ Million)
Table 92. APAC Influenza Medication Sales Quantity by Company (2018-2024) & (K Units)
Table 93. APAC Influenza Medication Revenue by Company (2018-2024) & (US$ Million)
Table 94. APAC Influenza Medication Sales Quantity by Type (2018-2024) & (K Units)
Table 95. APAC Influenza Medication Sales Quantity by Type (2024-2034) & (K Units)
Table 96. APAC Influenza Medication Revenue by Type (2018-2024) & (US$ Million)
Table 97. APAC Influenza Medication Revenue by Type (2024-2034) & (US$ Million)
Table 98. APAC Influenza Medication Sales Quantity by Application (2018-2024) & (K Units)
Table 99. APAC Influenza Medication Sales Quantity by Application (2024-2034) & (K Units)
Table 100. APAC Influenza Medication Revenue by Application (2018-2024) & (US$ Million)
Table 101. APAC Influenza Medication Revenue by Application (2024-2034) & (US$ Million)
Table 102. APAC Influenza Medication Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 103. APAC Influenza Medication Revenue by Region (2018-2024) & (US$ Million)
Table 104. APAC Influenza Medication Revenue by Region (2024-2034) & (US$ Million)
Table 105. APAC Influenza Medication Sales Quantity by Region (2018-2024) & (K Units)
Table 106. APAC Influenza Medication Sales Quantity by Region (2024-2034) & (K Units)
Table 107. Middle East, Africa and Latin America Influenza Medication Sales Quantity by Company (2018-2024) & (K Units)
Table 108. Middle East, Africa and Latin America Influenza Medication Revenue by Company (2018-2024) & (US$ Million)
Table 109. Middle East, Africa and Latin America Influenza Medication Sales Quantity by Type (2018-2024) & (K Units)
Table 110. Middle East, Africa and Latin America Influenza Medication Sales Quantity by Type (2024-2034) & (K Units)
Table 111. Middle East, Africa and Latin America Influenza Medication Revenue by Type (2018-2024) & (US$ Million)
Table 112. Middle East, Africa and Latin America Influenza Medication Revenue by Type (2024-2034) & (US$ Million)
Table 113. Middle East, Africa and Latin America Influenza Medication Sales Quantity by Application (2018-2024) & (K Units)
Table 114. Middle East, Africa and Latin America Influenza Medication Sales Quantity by Application (2024-2034) & (K Units)
Table 115. Middle East, Africa and Latin America Influenza Medication Revenue by Application (2018-2024) & (US$ Million)
Table 116. Middle East, Africa and Latin America Influenza Medication Revenue by Application (2024-2034) & (US$ Million)
Table 117. Middle East, Africa and Latin America Influenza Medication Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 118. Middle East, Africa and Latin America Influenza Medication Revenue by Country (2018-2024) & (US$ Million)
Table 119. Middle East, Africa and Latin America Influenza Medication Revenue by Country (2024-2034) & (US$ Million)
Table 120. Middle East, Africa and Latin America Influenza Medication Sales Quantity by Country (2018-2024) & (K Units)
Table 121. Middle East, Africa and Latin America Influenza Medication Sales Quantity by Country (2024-2034) & (K Units)
Table 122. Daiichi Sankyo Company Company Information
Table 123. Daiichi Sankyo Company Description and Overview
Table 124. Daiichi Sankyo Company Influenza Medication Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 125. Daiichi Sankyo Company Influenza Medication Product and Services
Table 126. Daiichi Sankyo Company Influenza Medication SWOT Analysis
Table 127. Daiichi Sankyo Company Recent Developments
Table 128. GlaxoSmithKline Company Information
Table 129. GlaxoSmithKline Description and Overview
Table 130. GlaxoSmithKline Influenza Medication Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 131. GlaxoSmithKline Influenza Medication Product and Services
Table 132. GlaxoSmithKline Influenza Medication SWOT Analysis
Table 133. GlaxoSmithKline Recent Developments
Table 134. Natco Pharma Company Information
Table 135. Natco Pharma Description and Overview
Table 136. Natco Pharma Influenza Medication Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 137. Natco Pharma Influenza Medication Product and Services
Table 138. Natco Pharma Influenza Medication SWOT Analysis
Table 139. Natco Pharma Recent Developments
Table 140. F. Hoffmann-La Roche Company Information
Table 141. F. Hoffmann-La Roche Description and Overview
Table 142. F. Hoffmann-La Roche Influenza Medication Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 143. F. Hoffmann-La Roche Influenza Medication Product and Services
Table 144. F. Hoffmann-La Roche Influenza Medication SWOT Analysis
Table 145. F. Hoffmann-La Roche Recent Developments
Table 146. Teva Pharmaceutical Company Information
Table 147. Teva Pharmaceutical Description and Overview
Table 148. Teva Pharmaceutical Influenza Medication Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 149. Teva Pharmaceutical Influenza Medication Product and Services
Table 150. Teva Pharmaceutical Influenza Medication SWOT Analysis
Table 151. Teva Pharmaceutical Recent Developments
Table 152. Sandoz International Company Information
Table 153. Sandoz International Description and Overview
Table 154. Sandoz International Influenza Medication Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 155. Sandoz International Influenza Medication Product and Services
Table 156. Sandoz International Influenza Medication SWOT Analysis
Table 157. Sandoz International Recent Developments
Table 158. Sun Pharmaceutical Industries Company Information
Table 159. Sun Pharmaceutical Industries Description and Overview
Table 160. Sun Pharmaceutical Industries Influenza Medication Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 161. Sun Pharmaceutical Industries Influenza Medication Product and Services
Table 162. Sun Pharmaceutical Industries Influenza Medication SWOT Analysis
Table 163. Sun Pharmaceutical Industries Recent Developments
Table 164. Mylan Company Information
Table 165. Mylan Description and Overview
Table 166. Mylan Influenza Medication Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 167. Mylan Influenza Medication Product and Services
Table 168. Mylan Influenza Medication SWOT Analysis
Table 169. Mylan Recent Developments
Table 170. Key Raw Materials Lists
Table 171. Raw Materials Key Suppliers Lists
Table 172. Influenza Medication Distributors List
Table 173. Influenza Medication Customers List
Table 174. Influenza Medication Market Trends
Table 175. Influenza Medication Market Drivers
Table 176. Influenza Medication Market Challenges
Table 177. Influenza Medication Market Restraints
Table 178. Research Programs/Design for This Report
Table 179. Key Data Information from Secondary Sources
Table 180. Key Data Information from Primary Sources
List of Figures
Figure 1. Influenza Medication Product Picture
Figure 2. Global Influenza Medication Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Influenza Medication Market Share by Type in 2022 & 2034
Figure 4. Zanamivir Product Picture
Figure 5. Oseltamivir Product Picture
Figure 6. Peramivir Product Picture
Figure 7. Amantadine Product Picture
Figure 8. Rimantadine Product Picture
Figure 9. Inosine Product Picture
Figure 10. Others Product Picture
Figure 11. Global Influenza Medication Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Figure 12. Global Influenza Medication Market Share by Application in 2022 & 2034
Figure 13. Hospitals
Figure 14. Clinics
Figure 15. Pharmacies
Figure 16. Others
Figure 17. Influenza Medication Report Years Considered
Figure 18. Global Influenza Medication Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 19. Global Influenza Medication Revenue 2018-2034 (US$ Million)
Figure 20. Global Influenza Medication Revenue Market Share by Region in Percentage: 2022 Versus 2034
Figure 21. Global Influenza Medication Sales Quantity 2018-2034 (K Units)
Figure 22. Global Influenza Medication Sales Quantity Market Share by Region (2018-2024)
Figure 23. Global Influenza Medication Sales Quantity Market Share by Region (2024-2034)
Figure 24. North America Influenza Medication Sales Quantity YoY (2018-2034) & (K Units)
Figure 25. North America Influenza Medication Revenue YoY (2018-2034) & (US$ Million)
Figure 26. Europe Influenza Medication Sales Quantity YoY (2018-2034) & (K Units)
Figure 27. Europe Influenza Medication Revenue YoY (2018-2034) & (US$ Million)
Figure 28. China Influenza Medication Sales Quantity YoY (2018-2034) & (K Units)
Figure 29. China Influenza Medication Revenue YoY (2018-2034) & (US$ Million)
Figure 30. APAC Influenza Medication Sales Quantity YoY (2018-2034) & (K Units)
Figure 31. APAC Influenza Medication Revenue YoY (2018-2034) & (US$ Million)
Figure 32. Middle East, Africa and Latin America Influenza Medication Sales Quantity YoY (2018-2034) & (K Units)
Figure 33. Middle East, Africa and Latin America Influenza Medication Revenue YoY (2018-2034) & (US$ Million)
Figure 34. The Top 10 and Top 5 Players Market Share by Influenza Medication Sales Quantity in 2022
Figure 35. The Top 10 and Top 5 Players Market Share by Influenza Medication Revenue in 2022
Figure 36. Influenza Medication Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 37. Global Influenza Medication Sales Quantity Market Share by Type (2018-2034)
Figure 38. Global Influenza Medication Revenue Market Share by Type (2018-2034)
Figure 39. Global Influenza Medication Sales Quantity Market Share by Application (2018-2034)
Figure 40. Global Influenza Medication Revenue Market Share by Application (2018-2034)
Figure 41. North America Influenza Medication Revenue Market Share by Company in 2022
Figure 42. North America Influenza Medication Sales Quantity Market Share by Company in 2022
Figure 43. North America Influenza Medication Sales Quantity Market Share by Type (2018-2034)
Figure 44. North America Influenza Medication Revenue Market Share by Type (2018-2034)
Figure 45. North America Influenza Medication Sales Quantity Market Share by Application (2018-2034)
Figure 46. North America Influenza Medication Revenue Market Share by Application (2018-2034)
Figure 47. North America Influenza Medication Revenue Share by Country (2018-2034)
Figure 48. North America Influenza Medication Sales Quantity Share by Country (2018-2034)
Figure 49. U.S. Influenza Medication Revenue (2018-2034) & (US$ Million)
Figure 50. Canada Influenza Medication Revenue (2018-2034) & (US$ Million)
Figure 51. Europe Influenza Medication Sales Quantity Market Share by Company in 2022
Figure 52. Europe Influenza Medication Revenue Market Share by Company in 2022
Figure 53. Europe Influenza Medication Sales Quantity Market Share by Type (2018-2034)
Figure 54. Europe Influenza Medication Revenue Market Share by Type (2018-2034)
Figure 55. Europe Influenza Medication Sales Quantity Market Share by Application (2018-2034)
Figure 56. Europe Influenza Medication Revenue Market Share by Application (2018-2034)
Figure 57. Europe Influenza Medication Revenue Share by Country (2018-2034)
Figure 58. Europe Influenza Medication Sales Quantity Share by Country (2018-2034)
Figure 59. Germany Influenza Medication Revenue (2018-2034) & (US$ Million)
Figure 60. France Influenza Medication Revenue (2018-2034) & (US$ Million)
Figure 61. U.K. Influenza Medication Revenue (2018-2034) & (US$ Million)
Figure 62. Italy Influenza Medication Revenue (2018-2034) & (US$ Million)
Figure 63. Russia Influenza Medication Revenue (2018-2034) & (US$ Million)
Figure 64. China Influenza Medication Sales Quantity Market Share by Company in 2022
Figure 65. China Influenza Medication Revenue Market Share by Company in 2022
Figure 66. China Influenza Medication Sales Quantity Market Share by Type (2018-2034)
Figure 67. China Influenza Medication Revenue Market Share by Type (2018-2034)
Figure 68. China Influenza Medication Sales Quantity Market Share by Application (2018-2034)
Figure 69. China Influenza Medication Revenue Market Share by Application (2018-2034)
Figure 70. APAC Influenza Medication Sales Quantity Market Share by Company in 2022
Figure 71. APAC Influenza Medication Revenue Market Share by Company in 2022
Figure 72. APAC Influenza Medication Sales Quantity Market Share by Type (2018-2034)
Figure 73. APAC Influenza Medication Revenue Market Share by Type (2018-2034)
Figure 74. APAC Influenza Medication Sales Quantity Market Share by Application (2018-2034)
Figure 75. APAC Influenza Medication Revenue Market Share by Application (2018-2034)
Figure 76. APAC Influenza Medication Revenue Share by Region (2018-2034)
Figure 77. APAC Influenza Medication Sales Quantity Share by Region (2018-2034)
Figure 78. Japan Influenza Medication Revenue (2018-2034) & (US$ Million)
Figure 79. South Korea Influenza Medication Revenue (2018-2034) & (US$ Million)
Figure 80. China Taiwan Influenza Medication Revenue (2018-2034) & (US$ Million)
Figure 81. Southeast Asia Influenza Medication Revenue (2018-2034) & (US$ Million)
Figure 82. India Influenza Medication Revenue (2018-2034) & (US$ Million)
Figure 83. Middle East, Africa and Latin America Influenza Medication Sales Quantity Market Share by Company in 2022
Figure 84. Middle East, Africa and Latin America Influenza Medication Revenue Market Share by Company in 2022
Figure 85. Middle East, Africa and Latin America Influenza Medication Sales Quantity Market Share by Type (2018-2034)
Figure 86. Middle East, Africa and Latin America Influenza Medication Revenue Market Share by Type (2018-2034)
Figure 87. Middle East, Africa and Latin America Influenza Medication Sales Quantity Market Share by Application (2018-2034)
Figure 88. Middle East, Africa and Latin America Influenza Medication Revenue Market Share by Application (2018-2034)
Figure 89. Middle East, Africa and Latin America Influenza Medication Sales Quantity Share by Country (2018-2034)
Figure 90. Middle East, Africa and Latin America Influenza Medication Revenue Share by Country (2018-2034)
Figure 91. Brazil Influenza Medication Revenue (2018-2034) & (US$ Million)
Figure 92. Mexico Influenza Medication Revenue (2018-2034) & (US$ Million)
Figure 93. Turkey Influenza Medication Revenue (2018-2034) & (US$ Million)
Figure 94. Israel Influenza Medication Revenue (2018-2034) & (US$ Million)
Figure 95. GCC Countries Influenza Medication Revenue (2018-2034) & (US$ Million)
Figure 96. Influenza Medication Value Chain
Figure 97. Influenza Medication Production Process
Figure 98. Channels of Distribution (Direct Vs Distribution)
Figure 99. Distributors Profiles
Figure 100. Bottom-up and Top-down Approaches for This Report
Figure 101. Data Triangulation
Figure 102. Key Executives Interviewed